PEPITEM

What is PEPITEM?

PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration) is a naturally occurring peptide derived from the 14-3-3 zeta delta protein, secreted by B cells in response to adiponectin signaling. Discovered by researchers at the University of Birmingham and published in Nature Medicine in 2015, PEPITEM acts as a built-in brake on inflammation — it selectively prevents T cells from crossing blood vessel walls into tissues, without affecting other immune cells. This pathway weakens with age and is impaired in autoimmune conditions like rheumatoid arthritis and type 1 diabetes, where circulating PEPITEM levels are measurably reduced. The concept of "PEPITEM replacement therapy" — supplementing what the body no longer produces enough of — is now being explored across multiple inflammatory and age-related conditions.

What PEPITEM Is Investigated For

PEPITEM is an endogenous immunoregulatory peptide — released by B cells downstream of adiponectin — being investigated as a replacement therapy across inflammatory arthritis, multiple sclerosis, lupus glomerulonephritis, psoriasis, osteoporosis, and age-related immune decline (inflammaging). The strongest evidence is preclinical, and across multiple independent disease models: animal inflammatory arthritis data showing effects comparable to infliximab, EAE models of MS with delayed onset and reduced CNS inflammation, halted osteoporosis-induced bone loss with stimulated new bone formation, and restored immune cell trafficking in aged mice. Ex vivo human blood studies confirm that circulating PEPITEM is reduced in rheumatoid arthritis, type 1 diabetes, and aging — mechanistically consistent with the replacement-therapy thesis. The critical gap is that no human clinical trial of any phase has been conducted; all efficacy data is preclinical, pharmacokinetics in humans are uncharacterized, and long-term safety of selective T-cell trafficking modulation has not been studied. Unlike older peptides, PEPITEM does not have a meaningful research-chemical supply — it is a preclinical research entity, not a self-experiment-ready product.

History & Discovery

PEPITEM was identified by the laboratory of Ed Rainger and Helen McGettrick at the University of Birmingham, with collaborators at the College of Medical and Dental Sciences and the Institute of Inflammation and Ageing. The discovery, published in Nature Medicine in 2015, emerged from work investigating how adiponectin — a hormone secreted by adipose tissue — exerts anti-inflammatory effects on T cell trafficking. The Birmingham group found that B cells, when stimulated by adiponectin, secrete a 14-amino-acid peptide derived from the 14-3-3 zeta/delta protein that selectively blocks T cell trans-endothelial migration without affecting other immune cells. They named it PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration). The broader biological insight is unusual and clinically appealing. Most anti-inflammatory drugs work by suppressing immune cell function broadly, with attendant infection-risk and immunosuppression side effects. PEPITEM works by restoring an endogenous regulatory signal that the body uses to dampen specifically T cell infiltration into tissues — leaving neutrophils, macrophages, and other arms of the immune system intact. The same Birmingham program subsequently showed that the adiponectin–PEPITEM axis is impaired in rheumatoid arthritis, type 1 diabetes, and aging, with measurably reduced circulating PEPITEM in patient serum. This positioned PEPITEM 'replacement therapy' — supplementing what the body no longer produces enough of — as a coherent therapeutic concept across multiple inflammatory and age-related conditions. The translational program has been actively expanding through the late 2010s and 2020s. Preclinical efficacy has been published in models of inflammatory arthritis (with effects comparable to infliximab), multiple sclerosis (EAE), lupus glomerulonephritis, psoriasis, peritonitis, age-related immune decline, and bone loss (where PEPITEM acts through a separate NCAM-1 pathway to stimulate osteoblast maturation). Active tripeptide pharmacophores and peptidomimetic analogues are being developed by the Birmingham group and commercial partners (notably Revolo Biotherapeutics) to enable practical drug development. Human clinical trials had not begun as of writing, but the volume of preclinical work and the mechanistic distinctiveness make PEPITEM one of the more interesting endogenous-replacement-therapy concepts in current inflammation biology.

How It Works

Your body naturally produces PEPITEM to keep inflammation in check. When adiponectin (a hormone from fat tissue) signals B cells, they release PEPITEM, which tells blood vessel walls to stop letting T cells (a type of immune cell) pass through into tissues. As you age or develop autoimmune conditions, this system breaks down — you produce less PEPITEM, and T cells flood into joints, organs, and tissues, causing chronic inflammation.

PEPITEM is proteolytically derived from the 14-3-3 zeta delta protein and released by B cells in response to adiponectin receptor activation. It binds cadherin-15 (CDH15) on vascular endothelial cells, activating sphingosine kinase 1 to synthesize sphingosine-1-phosphate (S1P). S1P is exported via the Spns2 transporter to the extracellular space, where it engages S1P receptor 1 (S1PR1) on adherent T cells. This signaling reduces T cell LFA-1 and endothelial ICAM-1 expression, selectively blocking T cell trans-endothelial migration without affecting neutrophil or monocyte recruitment. In bone tissue, PEPITEM acts through a separate NCAM-1-dependent pathway: it directly stimulates osteoblast maturation and new bone formation while triggering osteoprotegerin release that sequesters RANKL, limiting osteoclast-mediated bone resorption. The pathway is impaired in aging (reduced B cell PEPITEM secretion), rheumatoid arthritis, and type 1 diabetes, with measurably lower circulating PEPITEM in patient serum compared to healthy controls.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about PEPITEM:

• 01Any human clinical trial — no Phase I, II, or III study has tested PEPITEM in humans for safety, pharmacokinetics, or efficacy in any indication.
• 02Pharmacokinetics in humans — absorption, distribution, metabolism, and excretion of either the full 14-mer or the active tripeptide pharmacophores have not been characterized in humans.
• 03Optimal route and formulation — subcutaneous, intravenous, topical (psoriasis), and potentially intra-articular routes are conceivable; head-to-head data is absent.
• 04Disease-specific efficacy hierarchy — preclinical work spans many indications (arthritis, MS, lupus, psoriasis, bone loss, inflammaging); which indications offer the most favorable risk-benefit ratio for first-in-human trials is still being established.
• 05Long-term safety of selective T cell trafficking modulation — the selectivity for T cells (sparing other immune cells) is the appealing safety argument, but long-term immune surveillance and infection-risk implications need rigorous human study.
• 06Comparative efficacy versus established biologics — preclinical data shows comparability to infliximab in some models, but head-to-head human trials versus current standard-of-care biologics will be the meaningful translational test.
• 07Stratification by patient PEPITEM levels — circulating PEPITEM is reduced in RA, T1D, and aging; whether the reduction predicts response to replacement therapy is a natural personalized-medicine question that has not been addressed in trials.

Forms & Administration

PEPITEM has been administered via injection (intraperitoneal, subcutaneous) and topically in preclinical models. Active tripeptide pharmacophores and peptidomimetic analogues are being developed for improved delivery. It is not available for clinical use. All research peptides should only be used in the context of approved research protocols.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

PEPITEM has not been tested in humans in any published clinical trial and is not approved for any indication anywhere. Discussion of dosing here is for educational orientation about the underlying preclinical research, not guidance for use.

Timeline of Effects

Common Questions

Who PEPITEM Is NOT For

Drug & Supplement Interactions

There are no published clinical drug-interaction studies for PEPITEM in humans because human use does not exist outside preclinical research. What follows is mechanistic inference, not documented data. The most relevant theoretical interactions involve other immunomodulatory and anti-inflammatory drugs. With biologics targeting cytokine pathways (TNF inhibitors like infliximab and adalimumab; IL-6 inhibitors like tocilizumab; IL-17 inhibitors; JAK inhibitors), PEPITEM addresses a different layer of immune regulation (cell trafficking rather than cytokine signaling), so combinations could be either additive or partially redundant; the practical interaction profile would need to be characterized in human trials. With corticosteroids and conventional DMARDs (methotrexate, leflunomide, azathioprine), the same general framing applies — different mechanisms, unknown interaction profile, no data. With S1P receptor modulators (fingolimod, ozanimod, ponesimod), used in multiple sclerosis and inflammatory bowel disease, there is a more specific theoretical concern: PEPITEM's mechanism involves S1P generation as part of its signaling cascade, and pharmacologic modulation of the S1P axis is the explicit target of these drugs. Whether PEPITEM and S1P modulators would interact constructively, redundantly, or antagonistically in humans has not been studied. With standard cardiovascular, metabolic, and other non-immunologic medications, no specific interactions are predicted, but the overall picture is that human pharmacology is still to be established.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions